ArticleParasites & vectors2025
A non-randomized, open-label study to assess the impact of rounds of mass drug administration with artemisinin-piperaquine plus primaquine on malaria in São Tomé Island.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThe aim of this study was to explore the effect of mass drug administration (MDA) on malaria transmission in low-endemic malaria areas.
methodsMass drug administration of artemisinin-piperaquine (AP) + primaquine (PMQ) was targeted to 17,438 individuals in the Agua Grande region of São Tomé and Príncipe (STP). The participants were allocated to either a three-round MDA (3-MDA) group or to a two-round MDA (2-MDA) group. The coverage rate, compliance, adverse events and other indicators were evaluated.
resultsMass drug administration coverage rate in the 3-MDA group (20,548 person-times) was 84.23-89.14%, with a compliance of 68.38%. MDA coverage rate in the 2-MDA group (15,365 person-times) was 87.30-93.23%, with a compliance of 80.70%. The rates of MDA-related adverse reactions were low in both the 3-MDA (0.75%) and 2-MDA (0.72%) groups, and no serious adverse reactions were observed. Malaria incidence decreased by 80.47% (z = - 2.35, P = 0.019) and 72.27% (z = - 0.89, P = 0.372) in the 3-MDA and 2-MDA groups, respectively, within 1 year.
conclusionsTwo or three rounds of MDA with AP and PMQ in STP safely and rapidly reduced the prevalence of malaria cases and infections. It is possible that two rounds of MDA in certain districts may achieve the desired outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.